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ABSTRAK
Laporan kasus ini bertujuan untuk mengevaluasi respons terapi steroid pada endokarditis autoimun. Insidens 
penyakit jantung katup mengalami peningkatan dengan berbagai macam penyebab mulai dari kongenital 
sampai yang didapat, tetapi yang disebabkan oleh autoimun sangat jarang. Laporan kasus ini menyajikan 
kasus wanita, 34 tahun, dengan gejala dan tanda mirip lupus eritematosus sistemik (LES). Pada pemeriksaan 
penunjang didapatkan data yang mendukung adanya penyebab autoimun dan mengenai organ jantung. Pasien 
didiagnosis Libman-Sacks Endocarditis dan diberikan terapi steroid. Pasien mengalami perbaikan klinis dan 
struktural jantung setelah mendapatkan terapi selama 6 bulan. 
Kata kunci: lupus eritematosus sistemik (LES), steroid, Libman-sacks endocarditis.
ABSTRACT
This case study aim to evaluate the response of steroid treatment for autoimmune endocarditis. Valvular heart 
disease is relatively rising in both congenital and acquired cases, but the autoimmune endocarditis remains rare. 
In this case, a 34 year old woman with clinical manifestation resembling systemic lupus erythematosus (SLE) 
is diagnosed with Libman-sacks Endocarditis. After six months of steroid treatment, her clinical manifestations 
and heart structure improved.
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INTRODUCTION
Libman-Sacks endocarditis was first 
described in 1924 in four patients with atypical 
sterile verrucae lesions of the valvular and 
mural endocardium.1,2 These lesions were 
pathologically distinct from other etiologic 
endocarditis, were believed to be characteristic 
of systemic lupus erythematosus (SLE).2 This 
vegetation were found in 35%-65% in early 
autopsy studies but routinely were clinically 
silent and of minor hemodynamic importance.2,3 
Echocardiography diagnostic showed frequent 
occurrence of thickness and functionally 
impaired cardiac valves in SLE.1 There are two 
morphological types of valve lesion represent 
different stages of the same pathology process.1,2 
The shift in valve pathology has been ascribed 
to steroid therapy and generally long survival 
patient with SLE that allows more frequent 
emergence of fibroses, malfunctioning valve 
as the end-stage or healed from Libman-Sacks 
endocarditis.1,2
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The presence of anti-phospholipid antibodies 
(aPLs), determined as Immunoglobulin (Ig) 
G, Ig M or Ig A anti-Phospholipid cardiolipin 
antibodies (aCLs) and those identified in 
coagulation test are labelled as Las, was found 
to be associated with mitral or aortic verrucae 
valve thickening, global valve thickening and 
dysfunction, and mitral and aortic regurgitation.2 
Valve involvement has been shown to be 
influenced both by SLE disease duration and Ig G 
aCLs.2 It can reveal that the duration of SLE also 
affected myocardial function, whereas the aCLs 
were related only to the damaged endocardium.2 
The predominantly abnormal function is 
regurgitation, whereas stenosis is rarely seen.2 
The mitral is mainly affected, followed by 
the aortic valve.2 Additional involvement of 
the tricuspid or pulmonary valve has seldom 
identified.2 The valve lesions, as described in 
early pathological studies are sterile fibro-fibrous 
vegetation that may develop anywhere on the 
cardiac surface of the heart but with propensity 
for the left valves, particularly the ventricular 
space of the mitral valve.2
CASE ILLUSTRATION
A 34-year-old woman presented with new 
onset palpitation and exertional dyspnoea. 
She gave a history suggestive of SLE such as 
fever and shaking chills, cough, and rash spots 
in the chest and waist but without migratory 
arthralgia (only back pain), butterfly rash, and 
chest pain. On physical examination, heart rates 
(HR) was 80-100 beats/min, respiratory rates 
(RR) were 20 breaths/min and blood pressure 
(BP) 150/70 mmHg, a diastolic murmur, grade 
III-IV, in the apex while all other organs were 
unremarkable. Laboratory examination, show 
anti-nuclear antibody/ANA (-), double stranded 
Deoxyribonucleic acid (ds DNA), complement/
C3 83, Complement (C4). Other results were 
within normal limits. Electrocardiography (ECG) 
examination is normal but chest X-ray showed 
cardiomegaly with minimal pericardial effusion 
(PE). Echocardiography revealed dilated heart 
and global normal kinetic motion, severe mitral 
stenosis (MS), mild mitral regurgitation (MR) 
and tricuspid regurgitation (TR). Left ventricle 
In the above picture of pre-treatment, severe mitral stenosis (MS) was seen and (below picture of pre-treatment) 
vegetation in the mitral valve (MV) was seen. In the above picture of three months post treatment, moderate MS was 
observed and (below picture of post-treatment), no more vegetation was seen in the MV. In the above picture of six 
months post treatment, moderate MS was noted and in the below picture of six months, no vegetation or thrombus 
was observed in the MV.
Figure 1. Echocardiography results from pre-treatment to six months post treatment.
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(LV) and right ventricle (RV) functions were 
good, there was vegetation on mitral valve (MV), 
no thrombus, and ejection fraction (EF) was 
53%. According to these findings, the patient 
was diagnosed with autoimmune endocarditis 
with severe MS, mild MR and TR caused by 
SLE and anti-phospholipid syndrome (APS), 
and congestive heart failure (CHF) functional 
class I-II.
The patient was given methyl prednisolone 
1x 8 mg, then tapered down to 1x 4 mg, and 
oral anticoagulant (warfarin) 1x3 mg for six 
months. Subsequently, patient felt better. 
Echocardiography on follow-up, shows a global 
normal kinesis motion, moderate MS, LV and 
RV functions were good, vegetation on MV, 
thrombus (-), and EF is 64%. After six months of 
treatment, echocardiographic finding improved.
DISCUSSION
Based on diagnostic criteria of SLE, patient 
presented with malar rash, fever, reduced 
weight, and cardiac organ involvement.4-5 In 
addition, laboratory examination also support 
this diagnosis with Anti ds-DNA (+2), C3 (82) 
and C4 (12) but ANA (-).
According to echocardiography, we found 
mitral and tricuspid valve involvements that 
was severe mitral valve stenosis, mild mitral and 
tricuspid regurgitation. Therefore, the diagnosis 
for this patient is autoimmune disease caused by 
SLE and APS with severe mitral valve stenosis, 
mild mitral and tricuspid valve regurgitation.
According to the guidelines, there is no 
specific therapy to treat a patient with Libman-
Sacks endocarditis, but the management 
focused on heart failure due to the dysfunction 
of valves according to usual guidelines.1 
Because of the autoimmune aetiology, we gave 
corticosteroid for this patient. Corticosteroids 
are not beneficial and may even facilitate valve 
damage. Immunosuppressive agents should 
only be used for the treatment of an underlying 
condition.1
Steroids are used to control the autoimmune 
inflammation. After treatment for six months, 
the clinical manifestation disappeared and 
the cardiac valves improved. But patient’s 
bodyweight increased and appearance of her face 
became puffy with moon face. We suggest that 
the physician and cardiologist have to deal with 
the adverse effect of steroid treatment.2
Oral anticoagulants were given with caution 
to the patient in view of static flow that can be 
a risk factor for thrombosis and also for the 
vegetation in the MV wall. INR monitoring 
was done during oral anticoagulant treatment to 
prevent bleeding. We hope that early diagnosis 
can improve the patient’s outcome.
CONCLUSION
We conclude that this patient with 
autoimmune endocarditis has good response to 
six months steroid treatment and re-evaluation 
of clinical manifestations and cardiac structure 
should be performed routinely every 3 months 
by echocardiography.
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